Compare Poxel SA with Similar Stocks
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-96.41%
0%
-96.41%
6 Months
-96.96%
0%
-96.96%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Poxel SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.73%
EBIT Growth (5y)
14.27%
EBIT to Interest (avg)
-11.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
-0.82
Tax Ratio
1.90%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.30%
ROCE (avg)
0
ROE (avg)
0.19%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.22
EV to EBIT
-39.94
EV to EBITDA
-40.63
EV to Capital Employed
-29.26
EV to Sales
9.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Dec 2022
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (1.3%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
6.60
2.00
230.00%
Operating Profit (PBDIT) excl Other Income
-3.50
-12.00
70.83%
Interest
14.00
6.10
129.51%
Exceptional Items
0.30
0.20
50.00%
Consolidate Net Profit
-18.30
-35.10
47.86%
Operating Profit Margin (Excl OI)
-551.80%
-14,801.60%
1,424.98%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 230.00% vs 185.71% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 47.86% vs -11.78% in Dec 2023
About Poxel SA 
Poxel SA
Pharmaceuticals & Biotechnology
Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The Company cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Company Coordinates 
Company Details
Imm Le Sunway, 259/261 Avenue Jean Jaures LYON None : 69007
Registrar Details






